Drug profile · INN
doxycycline hyclate
DOXYCYCLINE HYCLATE
doxycycline hyclate (DOXYCYCLINE HYCLATE) is a matrix metalloproteinase-1 inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — doxycycline hyclate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 5
- Programs
- 18
- Data quality
- 0.89
Quick answer
doxycycline hyclate (DOXYCYCLINE HYCLATE) is a matrix metalloproteinase-1 inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Matrix metalloproteinase-1 inhibitor
Primary target: Bacterial 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 11219631
Foamable compositions, breakable foams and their uses
granted -
US 11103454
Wax foamable vehicle and pharmaceutical compositions thereof
granted -
US 11033491
Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
granted -
US 8652516
Doxycycline formulations, and methods of treating rosacea
granted -
US 7749532
Once daily formulations of tetracyclines
granted
Frequently asked questions
What is doxycycline hyclate?
doxycycline hyclate (DOXYCYCLINE HYCLATE) is a matrix metalloproteinase-1 inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for doxycycline hyclate?
DOXYCYCLINE HYCLATE is a marketed brand name for doxycycline hyclate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of doxycycline hyclate?
doxycycline hyclate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.